Matches in SemOpenAlex for { <https://semopenalex.org/work/W2160131861> ?p ?o ?g. }
- W2160131861 endingPage "2073" @default.
- W2160131861 startingPage "2061" @default.
- W2160131861 abstract "Chemotherapy treatment is the standard in triple negative breast cancers, a cancer subgroup which lacks a specific target. The mechanisms leading to the response, as well as any markers that allow the differentiation between responder and non-responder groups prior to treatment are unknown. In parallel, miRNAs can act as oncogenes or tumor suppressors and there is evidence of their involvement in promoting resistance to anticancer drugs. Therefore we hypothesized that changes in miRNA expression after doxorubicin treatment may also be relevant in treatment response.To study miRNAs that are differentially expressed in response to doxorubicin treatment.One luminal-A and two triple negative, breast cancer cell lines were exposed to doxorubicin. Microarray analysis was performed to identify the common and differentially modified miRNAs. Genes and pathways that are theoretically regulated by these miRNAs were analyzed.Thirteen miRNAs common to all three lines were modified, in addition to 25 that were specific to triple negative cell lines, and 69 that changed only in the luminal-A cell line. This altered expression pattern seemed to be more strongly related to the breast cancer subgroup than to the treatment. The analysis of target genes revealed that cancer related pathways were the most affected by these miRNAs, moreover many of them had been previously related to chemotherapy resistance; thus suggesting follow-up studies. Additionally, through functional assays, we showed that miR-548c-3p is implicated in doxorubicin-treated MCF-7 cell viability, suggesting a role for this miRNA in resistance." @default.
- W2160131861 created "2016-06-24" @default.
- W2160131861 creator A5001706445 @default.
- W2160131861 creator A5016066626 @default.
- W2160131861 creator A5020788113 @default.
- W2160131861 creator A5024025493 @default.
- W2160131861 creator A5025258875 @default.
- W2160131861 creator A5026179323 @default.
- W2160131861 creator A5029357603 @default.
- W2160131861 creator A5034653708 @default.
- W2160131861 creator A5038673543 @default.
- W2160131861 creator A5064018118 @default.
- W2160131861 date "2015-07-23" @default.
- W2160131861 modified "2023-10-16" @default.
- W2160131861 title "MicroRNA Profile in Response to Doxorubicin Treatment in Breast Cancer" @default.
- W2160131861 cites W1921728861 @default.
- W2160131861 cites W1965371218 @default.
- W2160131861 cites W1965568460 @default.
- W2160131861 cites W1969559178 @default.
- W2160131861 cites W1972572472 @default.
- W2160131861 cites W1973144992 @default.
- W2160131861 cites W1974025003 @default.
- W2160131861 cites W1981354547 @default.
- W2160131861 cites W1982535740 @default.
- W2160131861 cites W1983985456 @default.
- W2160131861 cites W1989504133 @default.
- W2160131861 cites W1993188287 @default.
- W2160131861 cites W1998967535 @default.
- W2160131861 cites W1999790032 @default.
- W2160131861 cites W1999929449 @default.
- W2160131861 cites W2002800994 @default.
- W2160131861 cites W2003631713 @default.
- W2160131861 cites W2007118283 @default.
- W2160131861 cites W2011694166 @default.
- W2160131861 cites W2018056391 @default.
- W2160131861 cites W2027873015 @default.
- W2160131861 cites W2035243232 @default.
- W2160131861 cites W2036224487 @default.
- W2160131861 cites W2056928766 @default.
- W2160131861 cites W2058493458 @default.
- W2160131861 cites W2063770678 @default.
- W2160131861 cites W2064955782 @default.
- W2160131861 cites W2069588389 @default.
- W2160131861 cites W2069653040 @default.
- W2160131861 cites W2070086300 @default.
- W2160131861 cites W2071676659 @default.
- W2160131861 cites W2072730515 @default.
- W2160131861 cites W2081113032 @default.
- W2160131861 cites W2084400739 @default.
- W2160131861 cites W2084526459 @default.
- W2160131861 cites W2085979770 @default.
- W2160131861 cites W2086299158 @default.
- W2160131861 cites W2096513091 @default.
- W2160131861 cites W2100810966 @default.
- W2160131861 cites W2102144501 @default.
- W2160131861 cites W2102596641 @default.
- W2160131861 cites W2105728472 @default.
- W2160131861 cites W2107910643 @default.
- W2160131861 cites W2112097782 @default.
- W2160131861 cites W2112136099 @default.
- W2160131861 cites W2115158844 @default.
- W2160131861 cites W2115727543 @default.
- W2160131861 cites W2118605519 @default.
- W2160131861 cites W2122493934 @default.
- W2160131861 cites W2122725298 @default.
- W2160131861 cites W2125120607 @default.
- W2160131861 cites W2125729223 @default.
- W2160131861 cites W2135601011 @default.
- W2160131861 cites W2140446903 @default.
- W2160131861 cites W2140725884 @default.
- W2160131861 cites W2141589190 @default.
- W2160131861 cites W2141884202 @default.
- W2160131861 cites W2142945152 @default.
- W2160131861 cites W2149385968 @default.
- W2160131861 cites W2149954427 @default.
- W2160131861 cites W2151091624 @default.
- W2160131861 cites W2151454553 @default.
- W2160131861 cites W2152395032 @default.
- W2160131861 cites W2154040159 @default.
- W2160131861 cites W2154142993 @default.
- W2160131861 cites W2154155138 @default.
- W2160131861 cites W2156205933 @default.
- W2160131861 cites W2157285286 @default.
- W2160131861 cites W2160563679 @default.
- W2160131861 cites W2162622637 @default.
- W2160131861 cites W2164194749 @default.
- W2160131861 cites W2170602872 @default.
- W2160131861 doi "https://doi.org/10.1002/jcb.25162" @default.
- W2160131861 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25802200" @default.
- W2160131861 hasPublicationYear "2015" @default.
- W2160131861 type Work @default.
- W2160131861 sameAs 2160131861 @default.
- W2160131861 citedByCount "28" @default.
- W2160131861 countsByYear W21601318612015 @default.
- W2160131861 countsByYear W21601318612016 @default.
- W2160131861 countsByYear W21601318612017 @default.
- W2160131861 countsByYear W21601318612018 @default.
- W2160131861 countsByYear W21601318612019 @default.